Quince Therapeutics tops 75% enrollment in pivotal Phase 3 NEAT clinical trial

Quince Therapeutics (QNCX) “announced that its pivotal Phase 3 NEAT clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study’s targeted 86 participants in the six to nine year-old primary analysis population. A total of 76 participants have been enrolled, including 65 participants in the six to nine year-old primary analysis population and 11 participants aged 10 years or older. Study powering based on currently enrolled participants is approximately 80%. The rate of screening and randomization activities has materially increased with the recent activation of all study sites. A total of 108 NEAT participants have been screened to date with a low screen failure rate of 10%. All 37 NEAT participants to date have elected to transition to the NEAT open label extension study. Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study.”